Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $2.7 million.

  • Exagen's Free Cash Flow rose 21489.45% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.2 million, marking a year-over-year decrease of 9407.07%. This contributed to the annual value of -$14.0 million for FY2024, which is 846.3% up from last year.
  • According to the latest figures from Q3 2025, Exagen's Free Cash Flow is $2.7 million, which was up 21489.45% from -$3.0 million recorded in Q2 2025.
  • Exagen's 5-year Free Cash Flow high stood at $8.2 million for Q4 2023, and its period low was -$12.5 million during Q2 2022.
  • For the 5-year period, Exagen's Free Cash Flow averaged around -$5.2 million, with its median value being -$5.9 million (2021).
  • Per our database at Business Quant, Exagen's Free Cash Flow tumbled by 15138.83% in 2021 and then skyrocketed by 23425.08% in 2023.
  • Exagen's Free Cash Flow (Quarter) stood at -$7.1 million in 2021, then increased by 13.65% to -$6.1 million in 2022, then soared by 234.25% to $8.2 million in 2023, then tumbled by 99.82% to $15000.0 in 2024, then surged by 17693.33% to $2.7 million in 2025.
  • Its Free Cash Flow stands at $2.7 million for Q3 2025, versus -$3.0 million for Q2 2025 and -$10.8 million for Q1 2025.